Building on condensate science, from concept to company



Condensates first observed

Peering through an early microscope, Santiago Ramón y Cajal saw membraneless structures now known to be condensates.



February, 2018Science

Potential of condensates identified

Phil Sharp identifies condensate biology as a once-in-a-generation opportunity to make transformative new medicines.

September, 2018Company

Dewpoint named

Founding team sketches out Dewpoint’s strategy. Suzanne Eaton, a brilliant scientist and partner to Tony Hyman, gives the company its name.

October, 2018Company

US operations begin


March, 2019Company

German operations begin

November, 2019Company

$100M deal with Bayer

Bayer and Dewpoint partner to research new treatments for cardiovascular and gynecological diseases.


September, 2020Company

Series B: $77M

Round led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors.


January, 2021Company

$239M deal with Pfizer

Dewpoint partners with Pfizer to develop potential therapies for a rare form of muscular dystrophy.


February, 2022Company

Series C: $150M

Round led by SoftBank Vision Fund 2, along with other new investors General Catalyst, Mubadala Capital, 3E Bioventures, Mirae Asset Capital, and NS Investment. Also joining the round were existing investors Leaps by Bayer, Polaris Partners, Samsara BioCapital, ARCH Venture Partners, EcoR1 Capital, and Maverick Ventures.